LPS 48 hour

Contact


Ms Rosanna Gillespie
+44 (0)20 7594 2151
r.gillespie@imperial.ac.uk

Lead academic
Professor Clare Lloyd

If you are interested in working with a particular group, please e-mail anyone of the Principal Investigators through the e-mail links on individual webpages.

Study with NHLI

What we do

The Inflammation Repair and Development (IRD) Section encompasses research in immunobiology of leukocytes, the blood cells that function as part of the body's immune system, integrated with investigation of developmental, environmental or medical factors that contribute to lung disease. We study diseases including asthma, chronic obstructive pulmonary disorder (COPD), cystic fibrosis, interstitial lung disease (ILD), respiratory infections and acute respiratory distress syndrome (ARDS). 

Why it is important

  1. Respiratory disease is a significant cause of mortality and morbidity worldwide, however effective treatments for many respiratory diseases are limited. At the same time certain medical interventions aimed at prolonging life, such as mechanical ventilation, can cause injury to the lungs which may lead to acute lung damage or long-term structural changes. Our section aims to identify new treatments to repair damaged lungs.
  2. A fundamental knowledge of the immunobiology of leukocytes is essential to understand how the body reacts to infection and injury. We investigate leukocyte development, from bone marrow, their recruitment, retention and recirculation through tissues and their role in maintenance of immune homeostasis within the lung as well as their contribution to host defence during infections.  

Impact of our research

Research by groups in our section has led to:

  1. A new sub-lingual (under the tongue) treatment for hayfever.
  2. Identified a novel class of drugs to reduce inflammation in chronic neutrophilic lung diseases such as COPD and severe asthma that are currently being developed for use in man.
  3. Pioneered tailored treatments for children with asthma by using age-appropriate in vivo models along with patient samples.
  4. Identified key proteins that are altered in in patients with idiopathic pulmonary fibrosis (IPF), these are currently being followed up in international clinical trials as potential treatment biomarkers.

Summary of current research

Our section's research encompasses two main areas: 

extra information

Events & meetings

  • Through the monthly IRD seminar series leading experts in the fields of inflammation, repair and development from around the UK and beyond present their work to the department. They also spend the day in the department, meeting the students, postdocs and Principal Investigators. 

Find out more about IRD Monday Seminar Series and Journal Club.

 

Key techniques

Key publications

Scadding GW, Calderon MA, Shamji MH, Eifan AO, Penagos M, Dumitru F, Sever ML, Bahnson HT, Lawson K, Harris KM, Plough AG, Panza JL, Qin T, Lim N, Tchao NK, Togias A, Durham SR. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial. JAMA. 2017 Feb 14;317(6):615-625. doi: 10.1001/jama.2016.21040.PMID: 28196255

Shamji MH, Durham SR. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol. 2017 Dec;140(6):1485-1498. doi: 10.1016/j.jaci.2017.10.010. Review. PMID: 29221580

Zhang Y, Poobalasingam T, Yates LL, Walker SA, Taylor MS, Chessum L, Harrison J, Tsaprouni L, Adcock IM, Lloyd CM, Cookson WO, Moffatt MF, Dean CH. Manipulation of dipeptidylpeptidase 10 in mouse and human in vivo and in vitro models indicates a protective role in asthma. Dis Model Mech. 2018 Jan 29;11(1). pii: dmm031369. doi: 10.1242/dmm.031369.

Toby M Maher, Ellen M van der Aar, Olivier Van de Steen, Lisa Allamassey, Julie Desrivot, Sonia Dupont, Liesbeth Fagard, Paul Ford, Ann Fieuw,
Wim Wuyts Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med. 2018 May 18. pii: S2213-2600(18)30181-4. doi: 10.1016/S2213-2600(18)30181-4

TM Maher, E Oballa, JK Simpson, J Porte, A Habgood, WA Fahy, A Flynn, PL Molyneaux,et Al., An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med. 2017 Dec;5(12):946-955. doi: 10.1016/S2213-2600(17)30430-7. Epub 2017 Nov 14

Loser S, Gregory LG, Zhang Y, Schaefer K, Walker SA, Buckley J, Denney L, Dean CH, Cookson WOC, Moffatt MF, Lloyd CMet al., 2017, Pulmonary ORMDL3 is critical for induction of Alternaria-induced allergic airways disease. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, Vol: 139, Pages: 1496-+, ISSN: 0091-6749

Public Engagement

As a section we are actively involved in public engagement activities for the department and Professor Sara Rankin is NHLI's Divisional Lead for Outreach.

We have recently received funding from the Wellcome Trust for a new project called Breathing Together - details will follow once the project launches in 2017.

Previous projects include:

For full details of all of NHLI's public engagement activities see our webpages.

Our researchers